PLK1 Inhibitors: Pioneering Precision Cancer Therapy

Tue, 30 Dec 2025 11:12:55 +0000

Polo-like kinase 1 (PLK1) has emerged as a pivotal regulator of cell division, making it a prime target in cancer research. Its critical role in mitotic progression has spurred the expansion of the PLK1 Inhibitor Market, as pharmaceutical and biotech innovators develop molecules designed to selectively disrupt PLK1 activity with minimal side effects. Growing preclinical evidence and the increasing focus on personalized oncology underscore the significance of PLK1-targeted interventions.